Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF-κB Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis
Table 1
Clinical characteristics and medications of the study population.
Characteristics
Statin (
No statin ()
value
Age, yr (IQR)
72.0 (66.0–77.3)
71.5 (67.3–76.7)
0.9249
Males, (%)
14 (53.8)
7 (58.3)
1.0000
CV risk factors
Blood pressure, mmHg
Systolic (IQR)
130.0 (125.0–141.3)
130.0 (125.0–140.0)
0.6826
Diastolic (IQR)
85.0 (80.0–90.0)
80.5 (80.0–84.5)
0.4686
Waist Circumference, cm (IQR)
91.0 (88.0–98.0)
91.5 (90.0–95.0)
0.7414
Current smoking, (%)
7 (26.9)
3 (25.0)
1.0000
Type 2 diabetes, (%)
11 (42.3)
3 (25.0)
0.4722
Dislipidemia, (%)
16 (61.5)
4 (33.3)
0.1643
Hypertension, (%)
21 (80.8)
10 (83.3)
1.0000
Chronic CAD*, (%)
7 (26.9)
3 (25)
1.0000
Carotid stenosis % lumen (IQR)
75 (70–80)
80 (70–85)
0.2349
Biological parameters
Total WBC†, number ×109/L (IQR)
6.35 (5.53–7.43)
6.56 (5.60–8.98)
0.4053
Neutrophils, number ×109/L (IQR)
3.90 (3.38–5.05)
4.36 (3.57–6.14)
0.4996
Lymphocytes, number ×109/L (IQR)
1.58 (1.24–1.96)
1.56 (1.12–1.84)
0.6716
Monocytes, number ×109/L (IQR)
0.37 (0.30–0.49)
0.44 (0.38–0.53)
0.0429
Red blood cells, number ×1012/L (IQR)
4.60 (4.10–4.85)
4.65 (4.53–5.00)
0.2513
Platelet, number ×109/L (IQR)
207.5 (178.8–238.8)
188.5 (175.5–219.8)
0.5096
Plasma fibrinogen, g/L (IQR)
3.65 (3.25–4.79)
4.09 (3.69–5.11)
0.3146
Serum total-c‡, mg/dl (IQR)
189.0 (164.0–215.0)
202.0 (159.3–209.3)
0.6150
Serum LDL-, mg/dl (IQR)
104.0 (81.2–130.0)
118.8 (77.0–132.2)
0.6380
Serum HDL-, mg/dl (IQR)
60.0 (41.5–69.0)
49.5 (41.5–64.0)
0.4754
Serum triglycerides, mg/dl (IQR)
124.0 (83.5–160.0)
85.0 (68.0–118.8)
0.2237
Serum glycaemia, mg/dl (IQR)
101.0 (96.5–153.0)
111.0 (95.8–124.0)
0.6497
Serum insulinemia, mU/L (IQR)
7.5 (5.8–16.3)
5.6 (3.7–12.2)
0.0747
Serum C-peptidemia, g/L (IQR)
2.35 (1.92–3.97)
2.06 (1.60–2.61)
0.1894
Antiplatelets, (%)
23 (88.5)
10 (83.3)
0.6426
Diuretics, (%)
2 (7.7)
4 (33.3)
0.0661
ACE# inhibitors, (%)
2 (7.7)
1 (8.3)
0.2295
ARBs**, (%)
11 (42.3)
6 (50.0)
0.7342
Beta-blockers, (%)
10 (38.5)
3 (25.0)
0.4859
Calcium channel blockers, (%)
9 (34.6)
4 (33.3)
1.0000
Oral antidiabetics, (%)
7 (26.9)
3 (25.0)
1.0000
Continuous variables are expressed as median (interquartile range (IQR)).
*CAD: coronary artery disease. †WBC: white blood cells. ‡total-c: total cholesterol. LDL-c: low-density lipoprotein cholesterol. HDL-c: high-density lipoprotein cholesterol.
#ACE: angiotensin converting enzyme.
**ARBs: angiotensin receptor blockers.
